8-K: Propanc Biopharma Secures $33,000 Convertible Note to Bolster Working Capital

Propanc Biopharma, Inc. has entered into a securities purchase agreement to issue a convertible promissory note for $33,000 to GS Capital Partners, LLC, aimed at enhancing the company's working capital.

Summary

• Propanc Biopharma, Inc. has secured a convertible promissory note for $33,000 from GS Capital Partners, LLC.
• The purchase price for the note was $30,000, reflecting a $3,000 original issue discount.
• The note bears an 8% interest rate and matures on November 11, 2025.
• The funds are intended for general working capital purposes.
• The note is convertible into common stock at a fixed price of $6.00 per share, subject to adjustments if the stock trades below $5.00 for five consecutive days, potentially reducing the conversion price to $3.00.
• In the event of default, the conversion price will be the lowest trading price of the common stock for the ten days prior to the default.
• The holder's conversion is capped at 4.99% of the outstanding shares, which can be increased to 9.9% with 60 days' notice.
• The company can prepay the note with premiums ranging from 110% to 125% of the principal plus accrued interest within the first 180 days.
• A reserve of 425,000 shares of common stock is to be maintained for conversions under the note.
• The company must maintain the listing of its common stock on the OTC Markets or an equivalent exchange.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document outlines a standard financing agreement. While it provides the company with needed capital, it also introduces potential dilution and financial obligations.

Positives

• The financing provides Propanc Biopharma with additional working capital.
• The convertible note structure allows for potential debt reduction through equity conversion.
• The prepayment option provides flexibility for the company to manage its debt.

Negatives

• The conversion of the note could dilute existing shareholders' equity.
• The company is obligated to maintain a listing on the OTC Markets or an equivalent exchange.
• The note contains events of default that could accelerate the repayment obligation.

Risks

• The potential for stock dilution if the note is converted into common stock.
• The risk of default if the company fails to meet its obligations under the note.
• The risk of delisting from the OTC Markets, which would trigger an event of default.
• The fluctuating conversion price based on stock performance could impact the number of shares issued upon conversion.

Future Outlook

The company intends to use the net proceeds from the note for general working capital purposes. The company is required to maintain a reserve of shares for potential conversion of the note.

Industry Context

This type of financing is common for small cap companies seeking to raise capital. Convertible notes can be attractive to investors as they offer both the potential for fixed income and equity upside.

Comparison to Industry Standards

• Comparable companies in the biopharmaceutical sector often utilize convertible notes for funding research and development or general operations.
• The terms of this note, such as the interest rate and conversion price, appear to be within the typical range for similar financings in the microcap market.
• The original issue discount of $3,000 on a $33,000 note is a fairly standard practice to incentivize investment in higher-risk ventures.

Stakeholder Impact

• Shareholders may experience dilution if the note is converted into common stock.
• The company's employees and operations will benefit from the increased working capital.
• The company's creditors will be impacted by the new debt obligation.

Next Steps

• The company will use the proceeds for working capital.
• The company will need to manage the share reserve for potential conversions.
• The company will need to monitor its stock price to manage the conversion price of the note.

Key Dates